Crinetics Pharmaceuticals Set for Financial Results Call
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) is gearing up to report its fourth quarter and full year financial results soon. This anticipated announcement, which will be made on February 27, 2025, follows a series of significant developments for the company and highlights its commitment to addressing critical endocrine diseases.
Understanding the Conference Call Details
The financial results will be shared after the market closes, and management is scheduled to host a conference call at 4:30 p.m. ET on the same day. This call is an opportunity for investors and stakeholders to gain insights into the company’s performance and strategic direction.
Join the Live Webcast
For those interested in participating, Crinetics offers two options: dialing in or joining a live webcast. The domestic callers can connect using 1-800-267-6316, while international participants can reach out via 1-203-518-9783. Remember to use Conference ID: CRNXQ4. To ensure a seamless connection, it is advisable to log in about 15 minutes early.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical-stage pharmaceutical enterprise dedicated to the discovery, development, and commercialization of groundbreaking therapeutics targeting endocrine diseases and related tumors. Known for its robust pipeline, Crinetics focuses on delivering innovative, orally administered drugs that are derived from its own drug discovery initiatives.
Current Development Focus
The company’s lead candidate, paltusotine, is under investigation for its potential to treat conditions like acromegaly and carcinoid syndrome linked with neuroendocrine tumors. In addition, Atumelnant is being developed for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome. The aim of these developments is clear: to provide effective, small-molecule treatments that address various endocrine disorders.
Crinetics also has active discovery programs tackling a plethora of endocrine conditions, including hyperparathyroidism, polycystic kidney disease, Graves’ disease (along with associated thyroid eye disease), diabetes, obesity, and oncology indications targeting GPCRs.
Investor Communications
Investors seeking more information can reach out to Gayathri Diwakar, Head of Investor Relations, at gdiwakar@crinetics.com or by calling (858) 345-6340. For media inquiries, Natalie Badillo serves as the Head of Corporate Communications and can be contacted at nbadillo@crinetics.com or (858) 345-6075.
Frequently Asked Questions
When will Crinetics Pharmaceuticals announce its financial results?
The announcement is scheduled for February 27, 2025, after the market closes.
How can I participate in the conference call?
You can participate by dialing 1-800-267-6316 for domestic calls or 1-203-518-9783 for international calls and using Conference ID: CRNXQ4.
What are the main products Crinetics Pharmaceuticals is working on?
The main products include paltusotine and Atumelnant, targeting conditions like acromegaly, congenital adrenal hyperplasia, and Cushing’s syndrome.
How can I access the webcast of the conference call?
You can join the webcast via a direct link provided in the company’s announcements or through their website.
Who should I contact for investor relations?
For investor inquiries, you can reach out to Gayathri Diwakar at gdiwakar@crinetics.com or call (858) 345-6340.
